Pharmaron Beijing Co., Ltd. (SHE:300759)

Pharmaron Beijing Revenue

Pharmaron Beijing had revenue of 4.02B CNY in the quarter ending June 30, 2026, with 20.19% growth. This brings the company's total for the last twelve months to 15.25B, up 16.30% year-over-year. In the year 2025, Pharmaron Beijing had annual revenue of 14.10B with 14.82% growth. That makes Pharmaron Beijing the 4,571st largest company in the world by revenue and 586th in China.

• Revenue (ttm): 15.25B
• Revenue Growth: +16.30%
• P/S Ratio: 4.13
• Revenue / Employee: 558.26K
• Employees: 27,316
• Market Cap: 62.21B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Laboratory Services (Excl. Macromolecule and Cell and Gene Therapy Services) 8.16B 57.9%
• CMC (Small Molecule CDMO) Service 3.48B 24.7%
• Clinical Development Services 1.96B 13.9%
• Biologics and CGT Services 474.69M 3.4%
• Others 21.90M 0.2%

By Geography

Chart

• North America 8.71B 61.8%
• Europe 2.89B 20.5%
• Mainland China 2.14B 15.2%
• Asia (Excluding Chinese Mainland) 298.44M 2.1%
• Others 50.69M 0.4%

Fiscal year ended Dec 31, 2025 See the full Pharmaron Beijing breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	14.10B	1.82B	14.82%
Dec 31, 2024	12.28B	737.78M	6.39%
Dec 31, 2023	11.54B	1.27B	12.39%
Jan 1, 2023	10.27B	2.82B	37.92%
Dec 31, 2021	7.44B	2.31B	45.00%

Data Source: S&P Global Market Intelligence Last updated: Aug 20, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error